Alerus Financial Corporation reports Q1 2026 results on April 29 with one striking signal in the data: options positioning has flipped to its most bullish extreme of the past year, just as short sellers pare back their bets.
The options story is the most unusual feature of this week's setup. The put/call ratio has collapsed to 0.03 — the 52-week low and well below its 20-day average of 0.96 — placing current positioning nearly 1.4 standard deviations below the mean. That reading marks a wholesale rotation toward calls and away from puts, a level of directional conviction rarely seen on a small-cap regional financial name. What changed around April 21 is clear in the history: the PCR sat around 1.48 for weeks, then snapped to its current extreme in a single session, suggesting a sharp repositioning rather than a gradual drift.
Short interest tells a quieter story, and one that supports the bullish lean. Bears have cut their exposure by roughly 10% over the past week, pulling short interest down to about 2.9% of the free float — a level that was closer to 3.3% at its recent peak in mid-April. The borrow market is loose: availability is ample, and cost to borrow, while nearly doubling over the past month to just under 1%, remains far too low to signal any squeeze dynamic. Short availability hit its tightest point of the past year back on March 27, when utilization touched 17.8%; it has since eased to around 10%, meaning there is plenty of room for new short interest to rebuild if results disappoint.
Analyst coverage is sparse and the most recent moves date from late January 2026. At that point, DA Davidson and Keefe, Bruyette & Woods both nudged their targets modestly higher — to $26 and $25 respectively — while maintaining neutral-leaning ratings. Raymond James carries the only outright bullish stance, with a Strong Buy and a $27 target. The consensus mean sits at $26.60, barely above the current price of $26.03, suggesting the Street sees little near-term upside beyond the current level even on a positive print. The P/E multiple has expanded roughly 0.9 points over the past 30 days to around 9.9x, and price-to-book has moved up meaningfully to 1.06x, reflecting the stock's 10% rise over the past month. The forward EPS growth score ranks in the 90th percentile — the standout factor in the profile — though the EPS surprise score is weak at just the 4th percentile, a reminder that Alerus has not historically beaten estimates by a wide margin.
On the institutional side, the ownership base is stable. Vanguard and Dimensional both added shares in the most recent quarter, while BlackRock made a small addition. The largest single holder remains Alerus itself at 8.96% of shares, followed by the ESOP at just over 3%. The most recent insider activity — from late February — consisted largely of routine equity award grants with modest accompanying tax-related sales from the CEO, COO, and two EVPs. Net insider activity over the 90-day window is a small positive at roughly $242,000, driven more by award grants than open-market purchases; the moves carry little directional signal.
The earnings history adds nuance. The most recent prior-quarter print on April 22 produced a barely-there 0.6% one-day move. The January 2026 result generated a 3.4% gain on the day and nearly 7% over the following week. With the stock already up 2.8% this week heading into tonight's release, the key question is whether the forward earnings growth story — the bull case rests on net interest margin expansion and non-interest income recovery — can close the gap between the Street's cautious targets and the stock's recent momentum. The bear case centres on continued loan runoff and deposit pressure. Tonight's print will test which of those narratives the numbers support.
See the live data behind this article on ORTEX.
Open ALRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
